Management of chronic urticaria in Asia: 2010 AADV consensus guidelines
10.5415/apallergy.2012.2.2.149
- Author:
Steven K W CHOW
1
Author Information
1. The KL Skin Centre, Pantai Hospital Kuala Lumpur, Kuala Lumpur, 59100, Malaysia. drstevenchow@gmail.com
- Publication Type:Review
- Keywords:
Asia;
Consensus;
Guideline;
Wheal;
Treatment;
Urticaria
- MeSH:
Asia;
Asian Continental Ancestry Group;
Consensus;
Cooperative Behavior;
Cyclosporine;
Dermatology;
Humans;
Quality of Life;
Urticaria;
Venereology
- From:
Asia Pacific Allergy
2012;2(2):149-160
- CountryRepublic of Korea
- Language:English
-
Abstract:
This guideline is a result of a consensus reached during the 19th Asian-Australasian Regional Conference of Dermatology by the Asian Academy of Dermatology and Venereology Study Group in collaboration with the League of Asian Dermatological Societies in 2010. Urticaria has a profound impact on the quality of life in Asia and the need for effective treatment is required. In line with the EAACI/GA2LEN/EDF/WAO guideline for the management of urticaria the recommended first-line treatment is new generation, non-sedating H1-antihistamines. If standard dosing is ineffective, increasing the dosage up to four-fold is recommended. For patients who do not respond to a four-fold increase in dosage of non-sedating H1-antihistamines, it is recommended that therapies such as H2-antihistamine, leukotriene antagonist, and cyclosporine A should be added to the antihistamine treatment. In the choice of second-line treatment, both their costs and risk/benefit profiles are the most important considerations.
